Science Applications International Corp
For the period ended Nov 1, 2024. Filed Dec 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Nov 1, 2024 · Filed Dec 5, 2024
SAIC$152.53+1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
| Nine Months Ended | ||
|---|---|---|
| November 1,2024 | November 3,2023 | |
| (in millions) | ||
| Cash flows from operating activities: | ||
| Net income | $264 | $438 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 104 | 106 |
| Deferred income taxes | (15) | (33) |
| Stock-based compensation expense | 38 | 42 |
| Gain on sale of equity method investments and long-lived assets | (5) | (3) |
| Gain on divestitures | — | (247) |
| Other | (4) | (1) |
| Increase (decrease) resulting from changes in operating assets and liabilities, net of the effect of divestitures: | ||
| Receivables | (108) | (142) |
| Prepaid expenses and other current assets | 31 | 13 |
| Other assets | 10 | 5 |
| Accounts payable and accrued liabilities | 121 | 120 |
| Accrued payroll and employee benefits | (59) | (4) |
| Income taxes payable | (2) | 21 |
| Operating lease assets and liabilities, net | (7) | (3) |
| Other long-term liabilities | 11 | 21 |
| Net cash provided by operating activities | 379 | 333 |
| Cash flows from investing activities: | ||
| Expenditures for property, plant, and equipment | (21) | (16) |
| Purchases of marketable securities | (11) | (6) |
| Sales of marketable securities | 10 | 5 |
| Proceeds from sale of long-lived assets | — | 3 |
| Proceeds from sale of equity method investments | 10 | — |
| Proceeds from divestitures | — | 356 |
| Cash divested upon deconsolidation of joint venture | — | (8) |
| Other | (3) | (10) |
| Net cash (used in) provided by investing activities | (15) | 324 |
| Cash flows from financing activities: | ||
| Dividend payments to stockholders | (57) | (60) |
| Principal payments on borrowings | (1,056) | (275) |
| Issuances of stock | 14 | 13 |
| Stock repurchased and retired or withheld for taxes on equity awards | (425) | (293) |
| Excise tax payments on stock repurchases | (3) | — |
| Proceeds from borrowings | 1,114 | 160 |
| Net cash used in financing activities | (413) | (455) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (49) | 202 |
| Cash, cash equivalents and restricted cash at beginning of period | 103 | 118 |
| Cash, cash equivalents and restricted cash at end of period | $54 | $320 |
-5-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.